AIM ImmunoTech (NYSE:AIM) Shares Gap Up to $1.29

AIM ImmunoTech Inc. (NYSE:AIM)’s stock price gapped up prior to trading on Friday . The stock had previously closed at $1.46, but opened at $1.29. AIM ImmunoTech shares last traded at $1.33, with a volume of 68,144 shares.

AIM has been the subject of a number of analyst reports. Maxim Group upgraded shares of AIM ImmunoTech from a “hold” rating to a “buy” rating in a report on Thursday, October 10th. TD Securities upgraded shares of AIM ImmunoTech to a “buy” rating and lifted their price objective for the company from $4.25 to $4.50 in a report on Tuesday, January 14th.

The firm has a market cap of $9.01 million, a PE ratio of -0.19 and a beta of 0.90. The company’s fifty day moving average price is $0.58. The company has a debt-to-equity ratio of 0.33, a current ratio of 3.01 and a quick ratio of 3.01.

AIM ImmunoTech (NYSE:AIM) last issued its quarterly earnings data on Thursday, November 14th. The company reported ($1.13) earnings per share (EPS) for the quarter. The firm had revenue of $0.06 million for the quarter.

A hedge fund recently bought a new stake in AIM ImmunoTech stock. Sabby Management LLC acquired a new stake in shares of AIM ImmunoTech Inc. (NYSE:AIM) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 185,171 shares of the company’s stock, valued at approximately $141,000. Sabby Management LLC owned about 2.24% of AIM ImmunoTech at the end of the most recent reporting period. Institutional investors and hedge funds own 15.41% of the company’s stock.

About AIM ImmunoTech (NYSE:AIM)

AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS).

Further Reading: Which market index is the best?

Receive News & Ratings for AIM ImmunoTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AIM ImmunoTech and related companies with's FREE daily email newsletter.


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit